Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. - Suppr | 超能文献

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

作者信息

Thaisrivongs S, Skulnick H I, Turner S R, Strohbach J W, Tommasi R A, Johnson P D, Aristoff P A, Judge T M, Gammill R B, Morris J K, Romines K R, Chrusciel R A, Hinshaw R R, Chong K T, Tarpley W G, Poppe S M, Slade D E, Lynn J C, Horng M M, Tomich P K, Seest E P, Dolak L A, Howe W J, Howard G M, Watenpaugh K D

机构信息

Upjohn, Inc., Kalamazoo, Michigan 49001, USA.

出版信息

J Med Chem. 1996 Oct 25;39(22):4349-53. doi: 10.1021/jm960541s.

DOI:10.1021/jm960541s

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

J Med Chem. 1996 Oct 25;39(22):4349-53. doi: 10.1021/jm960541s.

2

Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.

J Med Chem. 1996 Jun 7;39(12):2400-10. doi: 10.1021/jm950888f.

3

Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.

J Med Chem. 1996 Nov 8;39(23):4630-42. doi: 10.1021/jm960228q.

4

Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.

J Med Chem. 1997 Mar 28;40(7):1149-64. doi: 10.1021/jm960441m.

5

Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.

J Med Chem. 1996 Sep 27;39(20):4125-30. doi: 10.1021/jm960296c.

6

Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.

Bioorg Med Chem Lett. 1998 May 19;8(10):1237-42. doi: 10.1016/s0960-894x(98)00197-8.

7

Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

J Med Chem. 2005 May 19;48(10):3576-85. doi: 10.1021/jm050019i.

8

4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.

J Med Chem. 1997 Nov 7;40(23):3781-92. doi: 10.1021/jm970615f.

9

Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.

J Med Chem. 1995 Dec 22;38(26):4968-71. doi: 10.1021/jm00026a002.

10

Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.

J Med Chem. 2008 Feb 28;51(4):852-60. doi: 10.1021/jm701170f. Epub 2008 Jan 24.

引用本文的文献

1

Viral proteases as therapeutic targets.

Mol Aspects Med. 2022 Dec;88:101159. doi: 10.1016/j.mam.2022.101159. Epub 2022 Nov 29.

2

Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.

Int J Pharm. 2021 Jun 1;602:120621. doi: 10.1016/j.ijpharm.2021.120621. Epub 2021 Apr 21.

3

Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.

Front Microbiol. 2016 Feb 3;7:61. doi: 10.3389/fmicb.2016.00061. eCollection 2016.

4

Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease.

Biophys J. 2010 Sep 8;99(5):1650-9. doi: 10.1016/j.bpj.2010.06.064.

5

Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.

J Chem Inf Model. 2009 Dec;49(12):2851-62. doi: 10.1021/ci900320p.

6

Predicting drug resistance of the HIV-1 protease using molecular interaction energy components.

Proteins. 2009 Mar;74(4):837-46. doi: 10.1002/prot.22192.

7

Novel method for probing the specificity binding profile of ligands: applications to HIV protease.

Chem Biol Drug Des. 2008 May;71(5):387-407. doi: 10.1111/j.1747-0285.2008.00659.x. Epub 2008 Mar 31.

8

Evaluating the potency of HIV-1 protease drugs to combat resistance.

Proteins. 2008 May 15;71(3):1163-74. doi: 10.1002/prot.21808.

9

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

J Virol. 2006 Nov;80(21):10794-801. doi: 10.1128/JVI.00712-06. Epub 2006 Aug 23.

10

HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.

Protein Sci. 2004 Apr;13(4):1108-23. doi: 10.1110/ps.03468904.